Meeting
2014 Genitourinary Cancers Symposium
Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers to detect clinically significant disease: Results from the initial screening round of the IMPACT study.
Authors
Christos Mikropoulos
Institute of Cancer Research, Sutton, United Kingdom
Christos Mikropoulos , Elena Castro , Elizabeth Bancroft , Elizabeth Page , Natalie Taylor , Mahbubl Ahmed , Chee Leng Goh , Ros A. Eeles
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Prostate Cancer
Track
Prostate Cancer
Sub Track
Prostate Cancer
Clinical Trial Registration Number
NCT00261456
Citation
J Clin Oncol 32, 2014 (suppl 4; abstr 8)
DOI
10.1200/jco.2014.32.4_suppl.8
Abstract #
8
Poster Bd #
C8
Abstract Disclosures
Similar Posters
Poster
2015 Genitourinary Cancers Symposium
Prostate-specific antigen velocity as a predictive biomarker in a prospective prostate cancer screening study (IMPACT study).
First Author: Christos Mikropoulos
Poster
2012 ASCO Annual Meeting
Detecting prostate cancer in BRCA1 and BRCA2 mutation carriers: A role for EN2?
First Author: Emma Killick
Poster
2011 ASCO Annual Meeting
Correlation of germ-line BRCA2 mutations with aggressive prostate cancer and outcome.
First Author: E. Castro
Poster
2020 Genitourinary Cancers Symposium
Genomic characteristics associated with clinical activity of rucaparib in patients (pts) with BRCA1 or BRCA2 (BRCA)-mutated metastatic castration-resistant prostate cancer (mCRPC).
First Author: Wassim Abida